USV launches Pioz-V for uncontrolled diabetic patients with fatty liver

Mumbai: USV Pvt. Ltd, a leading drug manufacturer in the anti-diabetic segment, has announced the launch of the brand Pioz-V for the treatment of patients with uncontrolled diabetes with fatty liver.

Pioz-V is a fixed-dose combination (FDC) of Pioglitazone 15mg and Vildagliptin 50mg. It is approved by DCGI for the management of type 2 DM patients inadequately controlled on metformin monotherapy.

Pioglitazone, an oral antidiabetic drug, is a potent insulin sensitizer used for the treatment of type 2 diabetes mellitus in adults. It causes a durable reduction in HbA1C levels by reducing insulin resistance and corrects multiple components of metabolic syndrome and improves nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Vildagliptin is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme, promotes insulin secretion, and regulates blood glucose levels.

60% of people with diabetes suffer from Non-Alcoholic Fatty Liver Disease (NAFLD). People with uncontrolled diabetes, obesity, hypertension, dyslipidemia, and persistent high levels of ALT/AST enzymes are at higher risk. Pioglitazone has robust clinical data and is recommended by global guidelines for the management of NAFLD and vildagliptin provides complementary action in the management of Fatty Liver and HbA1c reduction.

Phase 3 trial conducted with Pioz V showed 1.3% reduction in HbA1c. Pioz-V offers a novel therapeutic approach in the management of fatty liver & HbA1C reduction which is now available widely across India.

USV Private Limited is an Indian multinational pharmaceutical and biotechnology company focused on the development of Active Pharmaceutical Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides, Biosimilars, and Injectables.

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by USV Pvt Ltd.